Samalizumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD200 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6542H10086N1702O2102S46 |
Molar mass | 147687.22 g·mol−1 |
![]() ![]() |
Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1] Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. [2]
Samalizumab was developed by Alexion Pharmaceuticals.
References
[edit]- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
- ^ "Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200". J Immunother Cancer 2019 Aug 23;7(1):227. doi: 10.1186/s40425-019-0710-.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.